title: PITASOR epidemiological study: prevalence, incidence and treatment of anaemia in radiation therapy oncology departments in Spain.
abstract: BACKGROUND
  Anemia is the most common haematological complication in cancer patients.
  
  
  OBJECTIVE
  Analysis of the incidence, prevalence and treatment of anemia in oncologic patients treated in Radiation Oncology Departments in Spain (ROD) and monitoring of the existing recommendations for the treatment of anemia.
  
  
  METHODS
  Observational, prospective, multicenter study which involved 19 Spanish ROD. The study was approved by the CEIC Central Defense Hospital. 477 patients with solid tumors, subsidiary of RT with radical intent referred to such centers within a period of one month (5/5/09 to 5/6/09) and gave their consent to participate in the study. We gathered the main characteristics of patients and their oncologic disease. All patients underwent a determination of Hb levels before RT, upon reaching 25-35 Gy and at the end treatment. In patients with anemia we assessed the existence of related symptoms and its treatment.
  
  
  RESULTS
  Basal situation: The prevalence of anemia was 34.8% (166 patients). Mean Hb in patients with anemia was 11.17 ± 1.07 g/dl. Anemia-related symptoms were present in 34% of the patients. Anemia predisposing factors were: stage of the disease, previously received chemotherapy, and hormonal therapy. 39% (66 patients) received anemia treatment, with a mean Hb of 10.43 ± 1.04 g/dl. During RT: The prevalence of anemia was 38.9% (182 patients) with a mean Hb of 11.24 ± 1.21 g/dl. Predisposing factors for anemia during RT treatment were: age, male sex, chemotherapy prior to RT, basal anemia and chemotherapy during RT. 36.3% (66 patients) had anemia-related symptoms. 34.6% (63 patients) with a mean Hb of 10.5 ± 1.37 g/dl received treatment for anemia. The prevalence of anemia at the end of the RT was 38.1% (177 patients) with a mean Hb of 11.19 ± 1.18 g/dl. The predisposing factors for the appearance of anemia at the end of RT were: male sex, anemia at basal situation and during treatment and chemotherapy during RT. 34% (61 patients) had anemia-related symptoms and 73 patients (41.2%) with a mean Hb of 10.5 ± 1.22 g/dl received treatment for anemia. The presence of anemia-related symptoms was significantly correlated with the beginning of treatment for anemia. The incidence of anemia (new cases) during radiotherapy was 17.5%.
  
  
  CONCLUSIONS
  The prevalence of anemia in basal situation, during RT and at the end of RT is 34.8%, 38.9% and 38.1%. During RT the incidence of anemia is 17.5%. 39.8%-41.2% of patients with anemia and 64.2%-68% of patients with anemia-related symptoms received treatment. Treatment of anemia starts with Hb<11 g/dl and the goal is to achieve Hb 12 g/dl. In our Radiotherapy Oncology Departments, the treatment of anemia complies with the current recommendations and guidelines in use.
authors: Servicio de Oncología Radioterápica, Hospital Central de Defensa Gómez Ulla, Madrid, Spain. psamots@oc.mde.es
authors: Pilar M
authors: PM
authors: Samper Ots
authors: Julia
authors: J
authors: Muñoz
authors: Albert
authors: A
authors: Biete
authors: María José
authors: MJ
authors: Ortiz
authors: María
authors: M
authors: Acuña
authors: Joaquín
authors: J
authors: Cabrera
authors: Concepción
authors: C
authors: López Carrizosa
authors: Eloisa
authors: E
authors: Bayo
authors: Ismael
authors: I
authors: Herruzo
authors: María Mar
authors: MM
authors: Pérez
authors: Miguel A
authors: MA
authors: Domínguez
authors: Virginia
authors: V
authors: Morillo Macías
authors: Moisés
authors: M
authors: Mira
authors: Ana María
authors: AM
authors: Pérez Casas
authors: María Mar
authors: MM
authors: Sevillano
authors: Isabel
authors: I
authors: García Ríos
authors: Francisco
authors: F
authors: Andreu
authors: Amalia
authors: A
authors: Sotoca
authors: Ana
authors: A
authors: Álvarez
authors: Escarlata
authors: E
authors: López
authors: María Ángeles
authors: MÁ
authors: Pérez Escutia
authors: Armando
authors: A
authors: Loayza Villaroel
references: Oncologist. 2000 Jun;5 Suppl 2:1-7
references: 10889268
references: Oncologist. 2007 Feb;12(2):231-42
references: 17296819
references: Lancet. 2003 Oct 18;362(9392):1255-60
references: 14575968
references: Eur J Cancer. 2004 Oct;40(15):2293-306
references: 15454256
references: Eur J Cancer. 2004 Oct;40(15):2201-16
references: 15454245
references: Cancer Treat Rev. 2006;32 Suppl 2:S1-3
references: 16725269
references: J Clin Oncol. 2002 Oct 1;20(19):4083-107
references: 12351606
references: Lancet Oncol. 2003 Aug;4(8):459-60
references: 12901958
references: Eur J Cancer. 2007 Jan;43(2):258-70
references: 17182241
references: J Clin Oncol. 1996 Feb;14(2):671-9
references: 8636786
references: Am J Med. 2004 Apr 5;116 Suppl 7A:11S-26S
references: 15050883